NLS Pharmaceutics News

Express News | NLS Pharmaceutics AG - Additional Bridge Loan Addendums Providing for Extension of Maturity Date Under Each of Loan Agreements to June 30, 2025

BreakingsMay 22 21:15

NLS Pharmaceuticals — Additional Transitional Loan Addendum to the Transitional Loan Agreement dated November 15, 2023 signed on May 16

NLS Pharmaceuticals — Additional Transitional Loan Addendum to the Transitional Loan Agreement dated November 15, 2023 signed on May 16

Zhitong FinanceMay 22 21:15

Express News | NLS Pharmaceutics - on May 16, Entered Into Additional Bridge Loan Addendums to Bridge Loan Agreement Dated Nov 15, 2023

BreakingsMay 22 21:14

20-F: Registration statement / Annual report / Transition report

SEC announcementMay 16 10:33 · Announcements

NLS Pharmaceutics Receives Nasdaq Staff Delisting Determination

Seeking AlphaApr 20 05:10

NLS Pharmaceutics Ltd Strategizes for Growth

TipRanksApr 16 09:02

Board Member Resigns From NLS Pharmaceutics Ltd.

TipRanksApr 9 04:58

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the

AccesswireMar 23 04:30

NLS Pharmaceutics Ltd. Announces New Warrant Issue

TipRanksMar 22 09:27

NLS Pharmaceutics Ltd. Addresses Financial Claims

TipRanksMar 21 01:57

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the

AccesswireMar 21 01:40

NLS Pharmaceutics Expands Neurological Therapy Options

TipRanksMar 20 22:28

NLS Pharmaceutics Secures Exclusive Global License For Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

NLS Pharmaceutics Secures Exclusive Global License For Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

BenzingaMar 20 19:39

NLS Pharmaceutics Extends Loan Maturity Date

TipRanksMar 20 18:57

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove

AccesswireMar 14 20:00

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove

AccesswireMar 11 19:00

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis

AccesswireFeb 23 20:30

NLS Pharmaceutics Announced Nasdaq Letter Related To Continued Listing Requirements

NLS Pharmaceutics Announced Nasdaq Letter Related To Continued Listing Requirements

BenzingaJan 13 05:33

Notice of Deficiency With Nasdaq Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the

AccesswireJan 13 05:30

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) today announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders.

AccesswireDec 30, 2023 05:30